Macular Degeneration Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Macular Degeneration stocks.

Macular Degeneration Stocks Recent News

Date Stock Title
Nov 21 APLS Apellis started at equal-weight at Morgan Stanley on geographic atrophy market
Nov 20 ADVM Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 19 REGN Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now
Nov 19 REGN Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript)
Nov 19 REGN Regeneron: The Biotech Stock To Buy Now
Nov 19 REGN Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3
Nov 18 REGN FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
Nov 18 ADVM Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients
Nov 18 RGNX Regenxbio surges 10% as it launches pivotal phase of muscular dystrophy asset trial
Nov 18 ADVM Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell
Nov 18 RGNX REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
Nov 18 ADVM Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
Nov 18 RGNX FDA endorses speedy approval path for Regenxbio Duchenne gene therapy
Nov 15 ADVM Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
Nov 15 RGNX Regenxbio down 13% ahead of data readout for muscular dystrophy asset
Nov 15 REGN FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
Nov 15 CLSD All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy
Nov 15 REGN Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S.
Nov 15 CLSD Clearside Biomedical Third Quarter 2024 Earnings: Beats Expectations
Macular Degeneration

Macular degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition which may result in blurred or no vision in the center of the visual field. Early on there are often no symptoms. Over time, however, some people experience a gradual worsening of vision that may affect one or both eyes. While it does not result in complete blindness, loss of central vision can make it hard to recognize faces, drive, read, or perform other activities of daily life. Visual hallucinations may also occur but these do not represent a mental illness.Macular degeneration typically occurs in older people. Genetic factors and smoking also play a role. It is due to damage to the macula of the retina. Diagnosis is by a complete eye exam. The severity is divided into early, intermediate, and late types. The late type is additionally divided into "dry" and "wet" forms with the dry form making up 90% of cases.Preventive efforts include exercising, eating well, and not smoking. Antioxidant vitamins and minerals do not appear to be useful for prevention. There is no cure or treatment that returns vision already lost. In the wet form, anti-VEGF medication injected into the eye or less commonly laser coagulation or photodynamic therapy may slow worsening. Supplements in those who already have the disease may slow progression.In 2015 it affected 6.2 million people globally. In 2013 it was the fourth most common cause of blindness after cataracts, preterm birth, and glaucoma. It most commonly occurs in people over the age of fifty and in the United States is the most common cause of vision loss in this age group. About 0.4% of people between 50 and 60 have the disease, while it occurs in 0.7% of people 60 to 70, 2.3% of those 70 to 80, and nearly 12% of people over 80 years old.

Browse All Tags